Our Science

Joseph Salvino, Ph.D.

Joseph Salvino, Ph.D.

  • Professor, Molecular and Cellular Oncogenesis Program
  • Scientific Director, Molecular Screening and Protein Expression Facility
Summary

Dr. Salvino’s research is directed at drug discovery and development. His lab focuses on early drug discovery and small molecule tool compounds for in vivo target validation to confirm the pharmacological relevance and “drugability” of a therapeutic target. Medicinal chemistry optimization is focused on the design and creation of new chemical analogs to understand structured activity relationships critical for optimizing an early stage compound series.  This effort is important to help identify a potential preclinical drug candidate or future therapeutic agent against a new biological target.

Salvino is the first medicinal chemist to join Wistar’s staff, and his work to identify novel small molecule lead compounds provides a strong basis for collaboration with all Wistar researchers.

Salvino has more than 20 years of experience in drug discovery, including early stage hit-to-lead, lead optimization, and preclinical development where several candidates have successfully completed human clinical trials, including Entereg®, ADL-101, and Radezolid®. Prior to joining Wistar, Salvino was a professor in the Department of Pharmacology and Physiology at Drexel University College of Medicine. Prior to that, he held high level positions including vice president, senior director, and director in the biotechnology and pharmaceutical industries of Sterling Winthrop, Rhone-Poulenc Rorer, Aventis, Rib-X Pharmaceuticals, Adolor Corporation, and Cephalon.

Salvino received his Ph.D. in Organic Chemistry from Brown University and completed postdoctoral training in synthetic and medicinal chemistry at the University of Pennsylvania under the mentorship of K.C. Nicolaou and Ralph F. Hirschmann.

Selected Publications

1.    Fatatis A, Shen F, Zhang Y, Jernigan D, Yan J, Garcia F, Meucci O, Salvino J. A novel small-molecule antagonist of CX3CR1 impairs metastatic seeding and colonization of breast cancer cells. Mol Cancer Res. 2016. doi:10.1158/1541-7786.MCR-16-0013.

2.    JM Salvino, YV Srikanth, R Lou, HM. Oyer, N Chen, FJ Kim. Novel Small Molecule Guanidine Sigma1 Inhibitors For Advanced Prostate Cancer. Bioorganic & Medicinal Chemistry Letters. 2017. doi: 10.1016/j.bmcl.2017.03.030.

3.    Tikhmyanova N, Salvino JM, Kossenkov AV, Kenney S, Lieberman, PM. Small Molecule Perturbtion of CAND1-Cullin-Ubiquitin Cycle Regulates Epstien-Barr Virus Reactivation from Latency. PLOS Pathogens, 2016. Pending.

4.    Tikhmyanova N, Schultz, DC, Lee T, Salvino, JM, Lieberman, PM. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr virus. ACS Chemical Biology, 2013. doi: 10.1021/cb4006326.

5.    Kopec K, Flood DG, Gasior M, McKenna BA, Zuvich E, Schreiber J, Salvino JM, Durkin JT, Ator MA, Marino MJ. Glycine Transporter (GlyT1) Inhibitors with Reduced Residence Time Increase Prepulse Inhibition without Inducing Hyperlocomotion in DBA/2 MiceBiochemical Pharmacology. 2010; 80(9): 1407-1417.

6.    Sundar BG, Bailey TR, Dunn DD, Bacon ER, Salvino JM, Morton GC, Aimone, LD, Zeqi H, Mathiasen JR, Dicamillo A, et al. Novel brain penetrant benzofuropiperidine 5-HT6 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 2012; 22(1): 120-123.

7.    Hirschmann R, Nicolaou KC, Pietranico P, Leahy EM, Salvino JM, Arison B, Cichy MA, Spoors PG, Shakespeare WC, et al. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing beta-D glucose as a novel scaffolding. Journal of the American Chemical Society. 1993; 15(26): 12550-12568.

8.    Dolle, RE, Prouty CP, Prasad CVC, Cook E, Saha A, Ross TM, Salvino JM, Helaszek CT, Ator MA. First Examples of Peptidomimetic Inhibitors of Interleukin-1 beta Converting Enzyme.  J. Med. Chem. 1996; 39(13): 2438-2440.

9.    Salvino JM,  Seoane PR, Douty BD, Awad MA, Hoyer D, Ross TM, Dolle RE, Houck WT, Faunce DM, Sawutz DG. Structure activity relationships of non-peptide bradykinin B2 receptor antagonists. Bioorg. Med. Chem. Lett. 1995; 5(4): 357-62.

10.  Salvino JM, Kumar NV, Orton E, Airey J, Kiesow T, Crawford K, Mathew R, Krolikowski P, Drew M, Engers D, Krolinkowski D, Herpin T, Gardyan M, McGeehan G, Labaudiniere R. Polymer-Supported Tetrafluorophenol: A New Activated Resin for Chemical Library Synthesis. Journal of Combinatorial Chemistry.  2000; 2(6): 691-697.

11.  Zhou L, Bhattacharjee A, Chen S, Chen Y, Duffy E, Farmer J, Goldberg J, Hanselmann R, Ippolito JA, Lou R, Orbin A, Oyelere A, Salvino, J, Springer D, Tran J, Wang D, Wu Y, Johnson G. Design at the atomic level: Design of biaryloxazolidinones as potent orally active antibiotics. Bioorganic & Medicinal Chemistry Letters. 2008; 18(23): 6175-6178.